glp-1 and gip dual agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care GLP-1 Receptor Agonists Explained for

Semaglutide mimics GLP-1 activity

Notably, epidemiological data indicate that Asian populations develop diabetes at a significantly younger age than White populations, exhibiting elevated risks of disease-related complications and mortality, thereby imposing a considerable healthcare burden [117]

Think of it this way: GLP-1 weight loss medication essentially gives your bodys natural appetite control system a significant boost

In the United States, FDA guidelines indicate these medications for: Adults with a BMI of 30 or higher (obesity) Adults with a BMI of 27 or higher who also have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea You should discuss GLP-1 medications with a physician if you have any of the following, as they may affect which medication is appropriate or require additional monitoring: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) a contraindication for all GLP-1 drugs History of pancreatitis Kidney disease or a history of gallstones Pregnancy or plans to become pregnant History of eating disorders The Critical Factor Most People Overlook: Muscle Loss Here is something that rarely appears in GLP-1 marketing: these medications can cause significant muscle loss alongside fat loss, particularly at the aggressive weight loss rates they enable

Liquid calories are the most common hidden saboteur of GLP-1 weight loss

Those who are may need to discontinue the drug before a procedure or fast for extended periods, and anesthesiologists must adjust their protocols accordingly